Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study
出版年份 2015 全文链接
标题
Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study
作者
关键词
-
出版物
Arthritis & Rheumatology
Volume 67, Issue 6, Pages 1424-1437
出版商
Wiley
发表日期
2015-03-02
DOI
10.1002/art.39093
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- FRI0020 Preclinical development of sarilumab, the first fully human monoclonal antibody (MAB) against IL-6r alpha: utilization and value of double humanized animal model
- (2014) L.-H. Wang et al. ANNALS OF THE RHEUMATIC DISEASES
- AB0037 Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human il-6 receptor (il-6r) alpha
- (2014) A. Rafique et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study
- (2014) Mark C Genovese et al. ANNALS OF THE RHEUMATIC DISEASES
- Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy
- (2014) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome data
- (2014) Cornelia Ursula Kunz et al. PHARMACEUTICAL STATISTICS
- When is a seamless study desirable? Case studies from different pharmaceutical sponsors
- (2014) Robert L. Cuffe et al. PHARMACEUTICAL STATISTICS
- Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes
- (2014) L. E. Macdonald et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice
- (2014) A. J. Murphy et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis
- (2014) Stanley Cohen et al. Arthritis & Rheumatology
- Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial
- (2013) Tom W J Huizinga et al. ANNALS OF THE RHEUMATIC DISEASES
- Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
- (2013) Michael Schiff et al. ANNALS OF THE RHEUMATIC DISEASES
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
- (2013) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study
- (2013) Désirée van der Heijde et al. ARTHRITIS AND RHEUMATISM
- The problem of choice: current biologic agents and future prospects in RA
- (2013) Ernest H. Choy et al. Nature Reviews Rheumatology
- Tocilizumab in rheumatoid arthritis: A meta-analysis of efficacy and selected clinical conundrums
- (2013) Geraldine Navarro et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate
- (2012) P Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Abstract 2723: Sarilumab (REGN88), a fully-human anti-IL6R antibody, inhibits tumor growth in preclinical models, as a single agent and in combination with the VEGF blocker aflibercept
- (2012) Li Zhang et al. CANCER RESEARCH
- Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy
- (2012) Maria A. Lopez-Olivo et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evolution of treatment for rheumatoid arthritis
- (2012) K. S. Upchurch et al. RHEUMATOLOGY
- Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis
- (2012) E. Choy RHEUMATOLOGY
- 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
- (2012) Jasvinder A. Singh et al. ARTHRITIS CARE & RESEARCH
- Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years
- (2011) M. U. Rahman et al. ANNALS OF THE RHEUMATIC DISEASES
- Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction
- (2011) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu
- (2010) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Tocilizumab for Rheumatoid Arthritis: A Cochrane Systematic Review
- (2010) J. A. SINGH et al. JOURNAL OF RHEUMATOLOGY
- Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials
- (2010) L. Campbell et al. RHEUMATOLOGY
- The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis
- (2010) Srinivasan Srirangan et al. Therapeutic Advances in Musculoskeletal Disease
- Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
- (2009) G. Jones et al. ANNALS OF THE RHEUMATIC DISEASES
- IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
- (2008) P. Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
- (2008) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started